ns3 protease inhibitor antiviral effects humans infected hepatitis c virus
hepatitis c virus hcv infection serious cause chronic liver disease worldwide million infected individuals risk developing significant morbidity mortality- current interferon-based therapies suboptimal especially patients infected hcv genotype poorly tolerated highlighting unmet medical need new therapeutics hcv-encoded ns3 protease essential viral replication long considered attractive target therapeutic intervention hcv-infected patients identify class specific potent ns3 protease inhibitors report evaluation biln small molecule inhibitor biologically available oral ingestion first class human trials administration biln patients infected hcv genotype days resulted impressive reduction hcv rna plasma levels established proof-of-concept humans hcv ns3 protease inhibitor results illustrate potential viral-enzyme-targeted drug discovery approach development new hcv therapeutics
